Serum Life Science Europe GmbH
Bacillus Calmette Guerin Vaccine(Serum Life Science Europe GmbH)은 Non-muscle Invasive Bladder Cancer 표적 ADC로, Non-muscle Invasive Bladder Cancer; HER-2 Protein Overexpression 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 0.96. 차별점: novel mathematical modeling-based framework provides a rigorous way of quantifying vaccine efficacy in ULD-infected mice, pav.
Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer; HER-2 Protein Overexpression
Recruiting
NK cells as well
novel mathematical modeling-based framework provides a rigorous way of quantifying vaccine efficacy in ULD-infected mice, pav
macrophage activation
escape), Rv1954A (role in macrophage activation/antigen presentation), and Rv2231A (role in persistence) were selected
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Serum Life Science Europe GmbH
Bacillus Calmette Guerin Vaccine(Serum Life Science Europe GmbH)은 Non-muscle Invasive Bladder Cancer 표적 ADC로, Non-muscle Invasive Bladder Cancer; HER-2 Protein Overexpression 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 0.96. 차별점: novel mathematical modeling-based framework provides a rigorous way of quantifying vaccine efficacy in ULD-infected mice, pav.
Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer; HER-2 Protein Overexpression
Recruiting
NK cells as well
novel mathematical modeling-based framework provides a rigorous way of quantifying vaccine efficacy in ULD-infected mice, pav
macrophage activation
escape), Rv1954A (role in macrophage activation/antigen presentation), and Rv2231A (role in persistence) were selected
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.